1. Aminoglycoside entry into gram-negative bacteria occurs in two sequential energy-dependent phases. A clinical pharmacologist is asked to explain why a patient with a serious intra-abdominal infection involving Bacteroides fragilis cannot be treated with gentamicin, even though in vitro susceptibility testing performed under aerobic conditions suggests activity. Which of the following correctly distinguishes energy-dependent phase I (EDP-I) from energy-dependent phase II (EDP-II) and identifies the phase whose failure explains intrinsic anaerobic resistance?

• A) EDP-I involves proton motive force (PMF)-driven active transport of aminoglycosides across the inner membrane into the cytoplasm; EDP-II involves electrostatic binding to lipopolysaccharide with divalent cation displacement at the outer membrane; anaerobic resistance results from failure of EDP-I because obligate anaerobes lack the electron transport chain required to sustain the PMF at the outer membrane.
• B) EDP-I and EDP-II are both passive diffusion processes requiring no energy input; the term "energy-dependent" refers to the drug's polycationic charge rather than active transport; anaerobic resistance results from constitutive expression of aminoglycoside-modifying enzymes that are upregulated under anaerobic metabolic conditions.
• C) EDP-I involves electrostatic binding of the polycationic aminoglycoside to lipopolysaccharide (LPS) at the outer membrane, displacing stabilizing divalent cations (Mg2+ and Ca2+) and disrupting outer membrane integrity; EDP-II involves PMF-driven active transport across the inner membrane into the cytoplasm; anaerobic resistance results from failure of EDP-II because obligate anaerobes lack an electron transport chain and cannot generate the PMF required for inner membrane transport.
• D) EDP-I involves PMF-driven aminoglycoside transport across the outer membrane; EDP-II involves ribosomal binding at the 30S subunit decoding site; anaerobic resistance results from absence of the 30S ribosomal subunit in obligate anaerobes, which use a structurally distinct ribosomal apparatus incompatible with aminoglycoside binding.
• E) EDP-I and EDP-II are functionally equivalent steps that can compensate for each other; if EDP-I is blocked by outer membrane impermeability, EDP-II increases its transport rate to maintain cytoplasmic accumulation; anaerobic resistance results from simultaneous failure of both phases due to absence of LPS and PMF in obligate anaerobes.

2. A clinical pharmacist is teaching a pharmacy resident about pharmacodynamic target attainment for aminoglycosides. She states that selecting the correct pharmacodynamic index and its target threshold is the foundation of every aminoglycoside dosing decision. Which of the following correctly identifies the pharmacodynamic index that drives aminoglycoside bactericidal efficacy, its target threshold against gram-negative organisms, and the pharmacodynamic category that distinguishes aminoglycosides from beta-lactam antibiotics?

• A) The primary pharmacodynamic index for aminoglycosides is the ratio of peak serum concentration to the minimum inhibitory concentration (Cmax/MIC); maximum bactericidal activity is achieved when this ratio exceeds 8–10 against gram-negative organisms; this classifies aminoglycosides as concentration-dependent killers, in contrast to beta-lactams, which are time-dependent killers whose efficacy is driven by the percentage of the dosing interval that serum concentrations remain above the MIC (%T>MIC).
• B) The primary pharmacodynamic index for aminoglycosides is the ratio of the 24-hour area under the concentration-time curve to the minimum inhibitory concentration (AUC24/MIC); a target of AUC24/MIC above 400 is required for bactericidal activity against gram-negative organisms; this is the same pharmacodynamic index that governs vancomycin activity against Staphylococcus aureus.
• C) The primary pharmacodynamic index for aminoglycosides is the percentage of the dosing interval during which serum drug concentration exceeds the minimum inhibitory concentration (%T>MIC); a target of %T>MIC above 50% of the dosing interval is required for bactericidal activity; this is the same time-dependent pharmacodynamic profile shared by carbapenems and cephalosporins.
• D) The primary pharmacodynamic index for aminoglycosides is the trough serum concentration relative to the minimum inhibitory concentration (Ctrough/MIC); a trough-to-MIC ratio above 4 is required to maintain continuous suppression of gram-negative bacterial growth between doses; this explains why maintaining elevated troughs is the primary goal of extended-interval dosing.
• E) Aminoglycosides have no reliable pharmacodynamic index because their bactericidal activity is saturable — once ribosomal binding sites are fully occupied, additional drug concentration produces no incremental killing; dosing is therefore guided entirely by toxicity avoidance rather than any efficacy pharmacodynamic target.

3. An infectious disease fellow explains to a medical student that the pharmacodynamic rationale for extended-interval aminoglycoside dosing rests on three complementary properties — not just the Cmax/MIC relationship alone. Which of the following correctly identifies the two additional pharmacodynamic phenomena that support extended-interval dosing and accurately describes the mechanism of each?

• A) The minimum bactericidal concentration (MBC) effect and the inoculum effect together support extended-interval dosing: bactericidal activity requires concentrations well above the MBC that are only achievable with once-daily high-dose infusions, and the inoculum effect means that killing is proportionally more complete at the lower bacterial densities present during the drug-free trough interval.
• B) The time-dependent post-antibiotic sub-MIC effect (PA-SME) and saturable ribosomal binding together support extended-interval dosing: sub-MIC concentrations suppress bacterial growth during the trough, and ribosomal saturation at peak concentrations means that splitting the dose across multiple daily infusions provides no additional bactericidal benefit beyond the first dose.
• C) The Eagle effect and the concentration-independent toxicity threshold together support extended-interval dosing: the Eagle effect means that bacterial killing paradoxically decreases at very high aminoglycoside concentrations, and once-daily dosing avoids this supraoptimal concentration range while the toxicity threshold is only crossed transiently during the brief infusion period.
• D) The post-antibiotic effect (PAE) and adaptive resistance together support extended-interval dosing: the PAE suppresses bacterial regrowth for 2–8 hours after concentrations fall below the MIC, extending antibacterial activity into the drug-free trough; adaptive resistance — a transient, reversible downregulation of EDP-II uptake that develops within hours of aminoglycoside exposure — resolves during the drug-free interval, restoring full bacterial susceptibility before the next dose.
• E) The concentration-dependent post-antibiotic leukocyte enhancement (PALE) effect and the prolonged tissue half-life together support extended-interval dosing: PALE means that immune cells kill aminoglycoside-exposed bacteria more efficiently for 12–24 hours after drug exposure, and aminoglycosides persist in tissue compartments between doses to sustain bactericidal concentrations at the site of infection throughout the trough interval.

4. A pharmacist is individualizing extended-interval gentamicin dosing for a 68-year-old man with gram-negative bacteremia and an estimated creatinine clearance of 48 mL/min. She draws a serum level 9 hours after the start of the 7 mg/kg infusion and plots it on the Hartford nomogram. Which of the following correctly describes the Hartford nomogram's methodology, what the single timed level determines, and a patient population for which the nomogram is not validated?

• A) The Hartford nomogram uses a peak level drawn 30–60 minutes after infusion completion and a trough level drawn immediately before the next dose; the ratio of these two levels determines the dosing interval; the nomogram is not validated for patients with a creatinine clearance below 60 mL/min.
• B) The Hartford nomogram uses a single serum level drawn between 6 and 14 hours after the start of a 7 mg/kg gentamicin or tobramycin infusion; the concentration plotted against the time of sampling determines the appropriate dosing interval — q24h, q36h, or q48h based on the zone in which the point falls; the nomogram is not validated for neonates, pregnant patients, patients with significant burns, or patients with ascites.
• C) The Hartford nomogram uses a single serum level drawn exactly at 8 hours after infusion completion regardless of the time the level is actually obtained; if the level is not drawn at precisely 8 hours, the nomogram cannot be used and alternative pharmacokinetic modeling is required; the nomogram is not validated for patients receiving concomitant vancomycin.
• D) The Hartford nomogram determines the milligram-per-kilogram dose rather than the dosing interval; the single level drawn 6–14 hours post-infusion is used to adjust the dose up or down while keeping the dosing interval fixed at every 24 hours for all patients regardless of renal function.
• E) The Hartford nomogram is used only for the initial dose calculation before therapy begins; once the first dose is administered, all subsequent dosing adjustments must be based on formal pharmacokinetic modeling using multiple serum levels; the nomogram cannot be used for ongoing monitoring during a course of therapy.

5. A 115 kg patient (ideal body weight 65 kg) with septic shock from gram-negative bacteremia and significant peripheral edema is being started on gentamicin. The clinical pharmacist explains that standard weight-based dosing requires two corrections in this patient — one for obesity and one for sepsis-related fluid shifts. Which of the following correctly describes the volume of distribution (Vd) of aminoglycosides in euvolemic adults, how sepsis alters this Vd, and the correct weight adjustment formula for obese patients?

• A) Aminoglycosides have a Vd of approximately 0.6–0.7 L/kg in euvolemic adults, reflecting extensive distribution into intracellular fluid and muscle tissue; sepsis decreases Vd by causing cellular dehydration and reducing tissue uptake; obese patients require dosing based on total body weight because the larger muscle mass significantly contributes to aminoglycoside distribution.
• B) Aminoglycosides have a Vd of approximately 0.05–0.1 L/kg in euvolemic adults, reflecting near-complete confinement to the plasma compartment; sepsis has no meaningful effect on this Vd because plasma volume changes in sepsis are small relative to total body water; obese patients require dosing based on lean body weight with no correction factor.
• C) Aminoglycosides have a Vd of approximately 0.25–0.3 L/kg in euvolemic adults but this Vd decreases substantially in septic patients because inflammatory cytokines cause renal vasoconstriction that reduces glomerular filtration and slows distribution kinetics; obese patients should use total body weight for dosing because adipose tissue becomes a significant reservoir for hydrophilic drugs during critical illness.
• D) Aminoglycosides have a Vd of approximately 0.25–0.3 L/kg in euvolemic adults, reflecting extracellular fluid distribution; sepsis increases Vd because intracellular fluid shifts out of cells into the extravascular space, creating an additional distribution compartment accessible to aminoglycosides that increases volume above the extracellular fluid baseline.
• E) Aminoglycosides have a Vd of approximately 0.25–0.3 L/kg in euvolemic adults, reflecting distribution primarily into extracellular fluid; this Vd increases substantially in septic patients with third-space fluid accumulation because expanded extracellular fluid volume dilutes drug distribution; obese patients require adjusted body weight (AdjBW = IBW + 0.4 × [total body weight minus IBW]) because adipose tissue contributes only partially to aminoglycoside distribution, and using total body weight would overestimate Vd and risk toxicity.

6. A patient with Enterococcus faecalis native valve endocarditis is receiving gentamicin as part of a synergy regimen using multiple-daily dosing (MDD). The attending physician asks the pharmacist to confirm the correct therapeutic drug monitoring targets for this indication, noting that the targets differ from those used when gentamicin is given for gram-negative bacteremia. Which of the following correctly states the MDD peak and trough concentration targets for gentamicin for both indications?

• A) For gram-negative infections, gentamicin MDD target peaks are 15–20 mcg/mL with troughs below 5 mcg/mL; for enterococcal synergy regimens, target peaks are 6–10 mcg/mL with troughs below 2 mcg/mL; the higher peaks for gram-negative infections reflect the greater intrinsic resistance of gram-negative bacteria compared to enterococci.
• B) For both gram-negative infections and enterococcal synergy regimens, gentamicin MDD target peaks are identical at 8–12 mcg/mL; the only difference between the two indications is the trough target — below 2 mcg/mL for gram-negative infections and below 1 mcg/mL for enterococcal synergy to reflect the longer duration of synergy regimens.
• C) For gram-negative infections, gentamicin MDD target peaks are 6–10 mcg/mL with troughs below 2 mcg/mL (ideally below 1 mcg/mL); for enterococcal synergy regimens, lower target peaks of 3–5 mcg/mL are used because synergistic bactericidal killing against enterococci is achieved at lower aminoglycoside concentrations when combined with a cell wall-active agent, while troughs should still be kept below 2 mcg/mL to limit nephrotoxicity risk.
• D) For gram-negative infections and enterococcal synergy regimens, the same MDD targets apply: peaks of 20–30 mcg/mL and troughs below 8 mcg/mL; these are the amikacin MDD targets that apply uniformly to all aminoglycosides regardless of the specific agent used.
• E) Gentamicin MDD targets are no longer clinically relevant because multiple-daily dosing has been completely replaced by extended-interval dosing for all indications including enterococcal endocarditis synergy; current guidelines recommend extended-interval dosing with Hartford nomogram monitoring for all patients receiving gentamicin regardless of indication.

7. A nephrology consultant is reviewing the mechanism and clinical pattern of aminoglycoside nephrotoxicity with a team of residents managing a patient who developed rising creatinine on day 9 of gentamicin therapy. She emphasizes that understanding the specific cellular mechanism and the typical temporal pattern of injury is essential for early recognition and prevention. Which of the following correctly describes the mechanism of aminoglycoside nephrotoxicity, the intracellular pathway leading to tubular cell death, and the characteristic clinical presentation?

• A) Aminoglycosides are filtered at the glomerulus and taken up by proximal tubular cells via the megalin-cubilin receptor complex on the luminal brush border; intracellular accumulation impairs mitochondrial function, disrupts lysosomal membranes (phospholipidosis), and generates reactive oxygen species (ROS), ultimately causing proximal tubular cell death; the clinical presentation is a non-oliguric acute kidney injury (AKI) that typically develops after 5–10 days of therapy, with serum creatinine rises that may lag behind actual tubular injury by 24–48 hours.
• B) Aminoglycosides cause nephrotoxicity by blocking the Na+/K+-ATPase pump in distal tubular cells, impairing the electrochemical gradient required for sodium reabsorption; the clinical presentation is a salt-wasting nephropathy with polyuria and hyponatremia appearing within the first 48 hours of therapy, distinguishing aminoglycoside nephrotoxicity from other drug-induced renal syndromes by its very early onset.
• C) Aminoglycosides cause nephrotoxicity by precipitating in acidic tubular urine and forming obstructing crystals in the collecting duct and papillary tips; the clinical presentation is an oliguric AKI with flank pain and hematuria that typically develops within 24–72 hours of initiating therapy, similar to the obstructive nephrotoxicity pattern seen with acyclovir at high doses.
• D) Aminoglycosides are secreted by proximal tubular cells and accumulate in the tubular lumen where they inhibit luminal carbonic anhydrase, impairing bicarbonate reabsorption and causing a type 2 (proximal) renal tubular acidosis; the clinical presentation is a normal anion gap metabolic acidosis without significant rise in serum creatinine or reduction in glomerular filtration rate.
• E) Aminoglycosides cause nephrotoxicity by triggering complement activation at the glomerular basement membrane, producing immune complex-mediated glomerulonephritis with proteinuria, hematuria, and red cell casts; the clinical presentation is a nephritic syndrome that typically develops in the second week of therapy in patients with pre-existing glomerular disease or prior aminoglycoside exposure.

8. An intern is writing admission orders for a 72-year-old patient with hospital-acquired pneumonia and a history of chronic kidney disease (CKD) stage 3. The attending physician plans to start empiric vancomycin plus tobramycin and asks the intern to identify which patient factors most significantly amplify the nephrotoxicity risk of this regimen. Which of the following correctly identifies the most important independent risk factors for aminoglycoside nephrotoxicity that should be assessed before initiating and during therapy?

• A) The principal risk factors for aminoglycoside nephrotoxicity are patient age below 30 years and female sex, as young patients have higher renal tubular megalin-cubilin expression and women have lower renal clearance relative to body surface area; these factors predict nephrotoxicity risk more reliably than drug-related parameters such as trough concentrations or concurrent medications.
• B) The principal risk factors for aminoglycoside nephrotoxicity are high peak concentrations and a Cmax/MIC ratio exceeding 15; once the Cmax/MIC target of 8–10 is achieved, no further risk stratification is required because efficacy-targeted dosing inherently prevents nephrotoxic drug accumulation regardless of other patient factors.
• C) The principal risk factors for aminoglycoside nephrotoxicity are hepatic impairment and thrombocytopenia; liver dysfunction reduces aminoglycoside protein binding, increasing free drug concentrations that accumulate in renal tubular cells, and thrombocytopenia predicts reduced glomerular perfusion pressure that sensitizes the kidney to tubular toxins.
• D) Independent risk factors for aminoglycoside nephrotoxicity include concurrent vancomycin administration (which markedly amplifies nephrotoxicity risk beyond either agent alone), pre-existing renal impairment, volume depletion, hypokalemia, hypomagnesemia, prolonged therapy duration beyond 5–7 days, elevated trough concentrations, older age, liver disease (particularly cirrhosis), and concomitant exposure to other nephrotoxins including amphotericin B, cisplatin, cyclosporine, and radiographic contrast agents.
• E) The only modifiable risk factor for aminoglycoside nephrotoxicity is the choice of once-daily versus multiple-daily dosing; all other patient-related factors including renal function, electrolyte status, volume status, and concurrent medications contribute negligible independent risk once extended-interval dosing is selected.

9. An otolaryngologist is consulted on a patient with bilateral high-frequency sensorineural hearing loss (SNHL) that developed after a prolonged course of amikacin for a multidrug-resistant gram-negative infection. The patient asks whether his hearing will recover with time. The consultant explains the pathophysiology of aminoglycoside cochleotoxicity and why the prognosis for recovery differs fundamentally from aminoglycoside nephrotoxicity. Which of the following correctly describes the cellular mechanism and anatomical pattern of aminoglycoside cochleotoxicity, and explains why recovery is not expected?

• A) Aminoglycosides cause cochlear ototoxicity by occluding the endocochlear vasculature through drug precipitation, producing ischemic injury to the spiral ganglion neurons that is reversible if the vascular occlusion resolves within 72 hours; the high-frequency hearing loss pattern reflects preferential ischemia of the apical cochlear turn, which has a lower-density capillary network than the basal turn.
• B) Aminoglycosides accumulate in cochlear hair cells via an active uptake mechanism, generating reactive oxygen species and activating apoptotic pathways that destroy the outer hair cells of the cochlear basal turn first (responsible for high-frequency hearing); because mammalian cochlear hair cells cannot regenerate after destruction, the resulting sensorineural hearing loss is permanent; initial injury produces high-frequency hearing loss that progresses toward speech frequencies with more severe or prolonged exposure.
• C) Aminoglycosides cause cochlear ototoxicity by inhibiting K+ recycling through gap junction channels in cochlear supporting cells, reducing the endocochlear potential required for hair cell mechanotransduction; this functional inhibition is reversible upon drug discontinuation because the supporting cells themselves are not destroyed and endocochlear potential recovers over weeks to months.
• D) Aminoglycosides cause cochlear ototoxicity by binding irreversibly to the tectorial membrane overlying outer hair cells, mechanically preventing hair cell deflection and blocking mechanotransduction; the tectorial membrane gradually degrades and remodels after drug discontinuation, allowing partial recovery of hearing over 12–24 months in most patients.
• E) Aminoglycosides cause cochlear ototoxicity through an immune-mediated delayed hypersensitivity reaction in the spiral ligament that is triggered by prior aminoglycoside exposure; a second course of aminoglycosides produces severe hearing loss in sensitized patients because memory T cells mount an accelerated inflammatory response against inner ear antigens, destroying the stria vascularis within days.

10. A pharmacology fellow is reviewing the differential ototoxic profiles of clinically used aminoglycosides to counsel a team managing patients on prolonged aminoglycoside courses. She explains that the pattern of ototoxic injury — vestibular versus cochlear predominance — differs by agent and predicts which symptoms will manifest first. Which of the following correctly pairs each aminoglycoside with its predominant ototoxic profile?

• A) Tobramycin and streptomycin are both preferentially vestibulotoxic, causing oscillopsia, vertigo, and gait instability before cochlear injury; amikacin and gentamicin are preferentially cochleotoxic, causing high-frequency sensorineural hearing loss before vestibular symptoms; neomycin has equivalent cochlear and vestibular toxicity.
• B) All clinically used aminoglycosides produce identical ototoxic profiles with simultaneous cochlear and vestibular injury progressing in parallel; agent-specific differences in ototoxic pattern are pharmacokinetic artifacts reflecting differences in peak concentration rather than intrinsic differential hair cell sensitivity to specific aminoglycosides.
• C) Amikacin is the most vestibulotoxic aminoglycoside and is the agent most likely to produce oscillopsia and gait instability during prolonged therapy; tobramycin is the most cochleotoxic and is the agent most likely to produce high-frequency sensorineural hearing loss; streptomycin has equal cochlear and vestibular toxicity.
• D) Gentamicin is the most cochleotoxic aminoglycoside, causing speech-frequency hearing loss before vestibular symptoms; streptomycin is the most nephrotoxic aminoglycoside and causes cochlear injury secondarily through uremia-related inner ear damage; neomycin is the safest aminoglycoside for patients with pre-existing hearing loss because it spares cochlear outer hair cells.
• E) Streptomycin and gentamicin are preferentially vestibulotoxic, causing oscillopsia, vertigo, and gait instability as predominant ototoxic manifestations; amikacin and tobramycin are preferentially cochleotoxic, causing high-frequency sensorineural hearing loss as the predominant manifestation; neomycin is the most cochleotoxic aminoglycoside overall and is absolutely contraindicated by systemic routes due to the severity of irreversible cochlear injury it produces.

11. A 34-year-old woman develops profound bilateral sensorineural hearing loss after receiving a single standard dose of gentamicin for a postoperative wound infection. Her mother became deaf after receiving streptomycin for tuberculosis decades ago, and a maternal aunt has also been told she should never receive aminoglycosides. Genetic testing is ordered. Which of the following best characterizes the genetic variant responsible for this family's extreme aminoglycoside cochlear susceptibility, its inheritance pattern, and its molecular mechanism?

• A) The family most likely carries a heterozygous pathogenic variant in the GJB2 gene (encoding connexin 26), which impairs gap junction-mediated K+ recycling in the cochlea; inheritance is autosomal recessive, explaining why the variant causes severe aminoglycoside sensitivity only in homozygous family members; heterozygous carriers have no increased aminoglycoside risk.
• B) The family most likely carries a gain-of-function variant in the SCN8A gene (encoding a neuronal voltage-gated sodium channel) that is expressed in spiral ganglion neurons; the variant causes hyperexcitability of auditory neurons, which amplifies the oxidative stress generated by aminoglycosides and produces hearing loss at drug concentrations that would not affect normal auditory neurons; inheritance is autosomal dominant.
• C) The family most likely carries the mitochondrial DNA variant A1555G — an adenine-to-guanine transition at position 1555 of the 12S ribosomal RNA gene — which alters the secondary structure of human mitochondrial 12S rRNA to more closely resemble the bacterial 16S rRNA targeted by aminoglycosides, dramatically increasing cochlear hair cell susceptibility; inheritance is exclusively maternal because mitochondria are transmitted only through the egg; even a single conventional aminoglycoside dose can trigger severe or profound SNHL in carriers.
• D) The family most likely carries a pathogenic variant in the KCNQ4 gene (encoding a K+ channel in outer hair cells) that reduces basal outer hair cell survival; aminoglycosides accelerate hair cell loss in KCNQ4 variant carriers by inhibiting the already-compromised K+ efflux pathway; inheritance is autosomal dominant, but the aminoglycoside sensitivity is dose-dependent and does not cause profound deafness after a single therapeutic dose.
• E) The family most likely carries a variant in the SLC26A4 gene (encoding pendrin) that impairs endolymphatic fluid reabsorption; the resulting endolymphatic hydrops dramatically increases aminoglycoside concentrations in endolymph relative to plasma; inheritance is autosomal recessive; the variant causes profound aminoglycoside sensitivity only when both alleles are affected.

12. A medical student is asked to describe the antibacterial spectrum of aminoglycosides and explain which agent is preferred for Pseudomonas aeruginosa infections and why. Which of the following correctly characterizes the spectrum of aminoglycoside activity, the class of organisms for which aminoglycosides have no useful activity due to a mechanistic limitation, and the basis for tobramycin's preference over gentamicin against Pseudomonas?

• A) Aminoglycosides are primarily active against aerobic gram-negative bacilli including Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae, Enterobacter species) and Pseudomonas aeruginosa; they have no useful activity against obligate anaerobes because these organisms lack an electron transport chain and cannot generate the PMF required for EDP-II inner membrane transport; tobramycin is preferred over gentamicin for Pseudomonas aeruginosa because it achieves approximately two- to four-fold lower minimum inhibitory concentrations against this organism, conferring superior intrinsic potency.
• B) Aminoglycosides are primarily active against aerobic gram-positive cocci including Staphylococcus aureus and Streptococcus pneumoniae when used as monotherapy; they have no useful activity against gram-negative organisms because the gram-negative outer membrane prevents polycationic drug entry; gentamicin is preferred over tobramycin for Pseudomonas aeruginosa because it achieves higher peak concentrations per milligram of administered dose.
• C) Aminoglycosides are primarily active against aerobic gram-negative bacilli and have no useful activity against fungi because fungal cell walls lack lipopolysaccharide (LPS), preventing EDP-I binding; tobramycin is preferred over gentamicin for Pseudomonas aeruginosa because tobramycin is metabolized more slowly by aminoglycoside-modifying enzymes present in Pseudomonas, effectively extending its intracellular half-life at the ribosomal binding site.
• D) Aminoglycosides are primarily active against aerobic gram-negative bacilli; they have no activity against Mycobacterium tuberculosis because the mycobacterial cell wall contains mycolic acids that prevent aminoglycoside outer membrane binding; amikacin is preferred over tobramycin for all Pseudomonas aeruginosa infections because its 1-N-acyl substituent increases intrinsic potency against Pseudomonas regardless of resistance enzyme expression.
• E) Aminoglycosides are primarily active against aerobic gram-negative bacilli and have synergistic activity against Streptococcus pneumoniae when combined with cell wall-active agents; they have no activity against intracellular pathogens such as Legionella pneumophila or Mycobacterium avium complex because aminoglycosides cannot penetrate host cell membranes; amikacin is preferred over tobramycin for routine Pseudomonas pneumonia in non-cystic fibrosis patients because amikacin achieves superior airway concentrations.

13. An infectious disease microbiologist is explaining why aminoglycoside resistance patterns can spread rapidly through a hospital unit, affecting multiple gram-negative species simultaneously. She describes the dominant clinical resistance mechanism and the genetic basis for its epidemiological behavior. Which of the following correctly identifies the three classes of aminoglycoside-modifying enzymes (AMEs), the chemical modification each performs, and the genetic feature responsible for their horizontal transmission among gram-negative pathogens?

• A) The three AME classes are beta-lactamases (BLs), carbapenemases (CPs), and extended-spectrum enzymes (ESEs); BLs hydrolyze the aminoglycoside ring structure, CPs inactivate the ribosomal binding moiety, and ESEs phosphorylate the terminal sugar residue; these enzymes are encoded on chromosomal mutations that are vertically transmitted from parent to daughter cells but cannot be transferred horizontally between species.
• B) The three AME classes are methyltransferases (RMTases), acetyltransferases (AACs), and efflux pumps (EPs); RMTases methylate the aminoglycoside molecule itself, AACs acetylate the 16S rRNA binding site, and EPs remove the drug before it reaches the ribosome; these resistance mechanisms are all encoded on chromosomal loci that are highly conserved across Enterobacteriaceae.
• C) The three AME classes are acetyltransferases (AACs), nucleotidyltransferases (ANTs), and phosphotransferases (APHs); AACs acetylate hydroxyl groups, ANTs adenylate amino groups, and APHs phosphorylate the aminocyclitol ring; the genes encoding these enzymes are chromosomally located and are not transferable between organisms, limiting spread to clonal expansion of resistant strains.
• D) The three AME classes are acetyltransferases (AACs), nucleotidyltransferases (ANTs), and phosphotransferases (APHs); AACs acetylate amino groups, ANTs adenylate (nucleotidylate) hydroxyl groups, and APHs phosphorylate hydroxyl groups on the aminoglycoside ring structure, abolishing the drug's ability to bind the 16S rRNA decoding site; the genes encoding these enzymes are carried on mobile genetic elements — plasmids, transposons, and integrons — enabling efficient horizontal transfer among Enterobacteriaceae, Pseudomonas, and Acinetobacter.
• E) The three AME classes are acetyltransferases (AACs), nucleotidyltransferases (ANTs), and phosphotransferases (APHs); however, these enzymes modify the bacterial ribosome rather than the aminoglycoside molecule, permanently altering the 30S subunit so that it no longer binds aminoglycosides; resistance persists in daughter cells after drug removal because the modified ribosome is replicated during bacterial cell division.

14. A Klebsiella pneumoniae blood culture isolate is reported as resistant to gentamicin and tobramycin but susceptible to amikacin, with susceptibility testing indicating AME-mediated resistance as the likely mechanism. The clinical pharmacist explains to the team why amikacin retains activity against this isolate and what structural feature is responsible. Which of the following correctly identifies the structural basis for amikacin's broader spectrum of activity in the setting of AME-mediated resistance, and states when amikacin should be selected over gentamicin or tobramycin?

• A) Amikacin retains activity because it is a prodrug that is converted to an active metabolite by a liver enzyme not expressed in bacteria; AMEs cannot inactivate the prodrug form, and the active metabolite reaches the ribosomal binding site before AMEs can act; amikacin should be selected as first-line therapy for all gram-negative infections regardless of local resistance patterns.
• B) Amikacin retains activity because its 1-N-acyl substituent — a bulky side chain at the 1-nitrogen position of the 2-deoxystreptamine aminocyclitol ring — creates steric hindrance that prevents most AMEs from accessing the hydroxyl and amino groups on the aminoglycoside ring that serve as modification sites; amikacin should be selected when gentamicin or tobramycin resistance is suspected or confirmed due to AME-mediated mechanisms, as it retains activity against most AME-carrying strains.
• C) Amikacin retains activity because it is administered at doses approximately three times higher than gentamicin, and the resulting high serum concentrations overwhelm AME enzymatic capacity; once AME saturation is achieved, residual unmodified amikacin reaches the ribosome in bactericidal concentrations; amikacin should be used first-line for all Pseudomonas infections because its higher dosing ensures superior Cmax/MIC ratios regardless of resistance.
• D) Amikacin retains activity because it uses an alternative active transport pathway across the inner bacterial membrane that bypasses the standard EDP-II mechanism; this alternative transport is not inhibited by AME activity because it delivers drug directly to the ribosome without passing through the cytoplasmic compartment where AMEs are located.
• E) Amikacin retains activity because its molecular weight is substantially lower than that of gentamicin and tobramycin, allowing it to diffuse through porin channels by passive means without requiring energy-dependent transport; AMEs are only active against aminoglycosides that use the EDP-II mechanism, so amikacin escapes inactivation by avoiding the transport step at which AMEs intercept their substrates.

15. A carbapenem-resistant Klebsiella pneumoniae isolate is reported as resistant to all aminoglycosides including amikacin, with MICs above 256 mcg/mL for gentamicin, tobramycin, and amikacin. The clinical microbiologist explains that this resistance profile is not consistent with standard AME-mediated resistance and that an additional genotypic test is being sent. Which of the following correctly identifies the resistance mechanism responsible for this pan-aminoglycoside phenotype including amikacin, explains why this mechanism overcomes amikacin's structural AME protection, and identifies the epidemiological association that makes this resistance mechanism particularly alarming?

• A) The pan-aminoglycoside resistance including amikacin is caused by a hyperproducing AAC(6')-Ib acetyltransferase variant that is capable of modifying the 1-N-acyl substituent of amikacin; unlike standard AAC(6')-Ib, the hyperproducing variant generates sufficient enzyme mass to overcome the steric protection conferred by amikacin's side chain; this variant is encoded on chromosomal mutations and does not transfer horizontally.
• B) The pan-aminoglycoside resistance is caused by simultaneous combined upregulation of three distinct AME classes (AAC, ANT, and APH) that together can overcome amikacin's 1-N-acyl steric protection through cooperative enzymatic action; MICs above 256 mcg/mL reflect the cumulative inactivation produced by all three enzyme classes acting simultaneously on each amikacin molecule.
• C) The pan-aminoglycoside resistance including amikacin is caused by loss-of-function mutations in both OmpK35 and OmpK36 outer membrane porin genes, completely eliminating aminoglycoside entry through the outer membrane; because EDP-I cannot occur without outer membrane penetration, no aminoglycoside — including amikacin — can reach the inner membrane transport system; MICs above 256 mcg/mL reflect complete outer membrane impermeability.
• D) The pan-aminoglycoside resistance including amikacin is caused by mutations in the gene encoding the EDP-II inner membrane transporter that abolish PMF sensitivity; the mutant transporter requires no PMF to function but transports aminoglycosides in the reverse direction — from cytoplasm to periplasm — actively effluxing drug as fast as it enters; this reverse-transport mechanism applies to all aminoglycosides regardless of structure.
• E) The pan-aminoglycoside resistance including amikacin is caused by a 16S rRNA methyltransferase (RMTase) — encoded by genes such as armA or rmtB — that methylates specific nucleotide residues at the aminoglycoside binding site of the 16S rRNA itself; because this modification targets the ribosomal binding site rather than the drug molecule, it overcomes amikacin's 1-N-acyl steric protection (which blocks AMEs from modifying the drug) and confers high-level resistance (MIC above 256 mcg/mL) to all aminoglycosides; RMTase genes are frequently co-located with carbapenemase genes such as NDM (New Delhi metallo-beta-lactamase) on the same mobile plasmids, creating organisms resistant to essentially all conventional antibacterial agents.

16. A pulmonologist managing a 22-year-old patient with cystic fibrosis (CF) — a genetic disorder caused by CFTR (cystic fibrosis transmembrane conductance regulator) dysfunction that impairs chloride transport and produces thick viscous secretions — needs to select an aminoglycoside regimen. The patient requires both treatment of an acute pulmonary exacerbation with intravenous therapy and a long-term plan for chronic Pseudomonas aeruginosa suppression. Which of the following correctly describes why CF patients require higher intravenous aminoglycoside doses than standard adults, and what inhaled aminoglycoside formulation is approved for chronic Pseudomonas suppression in CF?

• A) CF patients require lower intravenous aminoglycoside doses because CFTR dysfunction causes renal tubular acidosis that reduces renal aminoglycoside clearance, resulting in drug accumulation at standard doses; for chronic Pseudomonas suppression, inhaled colistin is the only approved inhaled antibacterial agent in CF patients and inhaled tobramycin is not available in an approved formulation.
• B) CF patients require the same intravenous aminoglycoside doses as non-CF adults of equivalent weight because CFTR dysfunction does not alter aminoglycoside pharmacokinetics; the only dosing difference is that more frequent therapeutic drug monitoring is recommended to detect early nephrotoxicity; for chronic Pseudomonas suppression, intravenous tobramycin at reduced dose is preferred over inhaled formulations because systemic drug delivery is required to suppress biofilm-associated Pseudomonas in bronchiectatic airways.
• C) CF patients require higher intravenous aminoglycoside doses — typically tobramycin 8–10 mg/kg/day or higher — because altered body composition and enhanced renal tubular secretion produce a markedly increased volume of distribution and augmented renal clearance that result in lower peak concentrations and faster drug elimination than expected at standard doses; for chronic Pseudomonas suppression, inhaled tobramycin inhalation solution (TIS) or tobramycin inhalation powder (TIP) is approved and achieves high airway concentrations with minimal systemic absorption, reducing exacerbation frequency and slowing pulmonary decline.
• D) CF patients require higher intravenous aminoglycoside doses because CFTR dysfunction activates hepatic CYP3A4, accelerating aminoglycoside metabolism; the increased hepatic clearance reduces serum half-life and necessitates dose escalation to maintain therapeutic Cmax/MIC ratios; for chronic Pseudomonas suppression, inhaled amikacin is the only approved inhaled aminoglycoside because tobramycin is too viscous for nebulization in patients with thick airway secretions.
• E) CF patients require higher intravenous aminoglycoside doses because thick airway mucus sequesters tobramycin within bronchial secretions, reducing serum bioavailability and requiring higher systemic doses to compensate for drug lost to mucus binding; inhaled tobramycin is contraindicated in CF patients with FEV1 (forced expiratory volume in 1 second) below 25% predicted because it triggers severe bronchospasm in patients with advanced obstruction.